Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
PF-07852352 Influenza saRNA 1 · 1 trial · 1 indication
Pain at the injection site, redness, and swelling, as self-reported in electronic diaries.
Fever, fatigue, headache, chills, vomiting, diarrhea, new or worsened muscle pain, and new or worsened joint pain, as self reported in electronic diaries.
As elicited by investigational site staff.
As elicited by investigational site staff.
As measured at the central laboratory
As measured at the central laboratory.
ECG abnormalities consistent with probable or possible myocarditis or pericarditis, as judged by a cardiologist
ECG abnormalities consistent with probable or possible myocarditis or pericarditis, as judged by a cardiologist
| Arm | Type | Description |
|---|---|---|
| PF-07852352 Influenza saRNA, low dose | EXPERIMENTAL | - |
| PF-07852352 Influenza saRNA, mid dose | EXPERIMENTAL | - |
| PF-07852352 Influenza saRNA, high dose | EXPERIMENTAL | - |
| PF-07836391 Influenza saRNA, low dose | EXPERIMENTAL | - |
| PF-07836391 Influenza saRNA, mid dose | EXPERIMENTAL | - |
| PF-07836391 Influenza saRNA, high dose | EXPERIMENTAL | - |
| PF-07836394 Influenza saRNA, low dose | EXPERIMENTAL | - |
| PF-07836394 Influenza saRNA, mid dose | EXPERIMENTAL | - |
| PF-07836394 Influenza saRNA, high dose | EXPERIMENTAL | - |
| PF-07836395 Influenza saRNA, low dose | EXPERIMENTAL | - |
| PF-07836395 Influenza saRNA, mid dose | EXPERIMENTAL | - |
| PF-07836395 Influenza saRNA, high dose | EXPERIMENTAL | - |
| PF-07836396 Influenza saRNA, low dose | EXPERIMENTAL | - |
| PF-07836396 Influenza saRNA, mid dose | EXPERIMENTAL | - |
| PF-07836396 Influenza saRNA, high dose | EXPERIMENTAL | - |
| PF-07867246 Influenza saRNA, mid dose | EXPERIMENTAL | - |
| PF-07867246 Influenza saRNA, low dose | EXPERIMENTAL | - |
| PF-07867246 Influenza saRNA, high dose | EXPERIMENTAL | - |
| Placebo | PLACEBO_COMPARATOR | - |
| Quadrivalent influenza vaccine (QIV) | ACTIVE_COMPARATOR | - |
| PF-07871987 Influenza saRNA, low dose | EXPERIMENTAL | - |
| PF-07871987 Influenza saRNA, mid dose | EXPERIMENTAL | - |
| PF-07871987 Influenza saRNA, high dose | EXPERIMENTAL | - |
| PF-07914705 Influenza saRNA mid dose | EXPERIMENTAL | - |
| PF-07914705 Influenza saRNA, high dose | EXPERIMENTAL | - |
| PF-07915048 Influenza saRNA, high dose | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| PF-07852352 Influenza saRNA 1 | BIOLOGICAL | Intramuscular injection |
| PF-07836391 Influenza saRNA | BIOLOGICAL | Intramuscular injection |
| PF-07836394 Influenza saRNA | BIOLOGICAL | Intramuscular injection |
| PF-07836395 Influenza saRNA | BIOLOGICAL | Intramuscular injection |
| PF-07836396 Influenza saRNA | BIOLOGICAL | Intramuscular injection |
| PF-07867246 Influenza saRNA | BIOLOGICAL | Intramuscular injection |
| Placebo | BIOLOGICAL | Intramuscular injection |
| Quadrivalent influenza vaccine (QIV) | BIOLOGICAL | Intramuscular injection |
| PF-07871987 Influenza saRNA | BIOLOGICAL | Intramuscular injection |
| PF-07914705 Influenza saRNA | BIOLOGICAL | Intramuscular injection |
| PF-07915048 Influenza saRNA | BIOLOGICAL | Intramuscular injection |
Inclusion Criteria: * Male or female participants 18 to 49 years of age. * Participants who are willing and able to comply with all scheduled visits, treatment plan, laboratory tests, lifestyle considerations, and other study procedures. * Healthy participants who are determined by medical history,...
PF-07852352 Influenza saRNA 1 is an investigational vaccine being studied for the prevention of influenza in humans. It is currently in Phase 1 clinical development and is not yet approved by regulatory authorities.
PF-07852352 Influenza saRNA 1 is being developed by Pfizer, Inc., a biopharmaceutical company traded on the New York Stock Exchange under the ticker symbol PFE.
PF-07852352 Influenza saRNA 1 is in Phase 1 clinical development. It is an investigational vaccine and has not been approved for use. One Phase 1 trial has been completed.
PF-07852352 Influenza saRNA 1 has been studied in one completed Phase 1 trial, NCT05227001, which enrolled 440 participants in the United States. The trial was randomized, double-blind, and placebo-controlled, and included healthy volunteers aged 18 years and older.
Yes, PF-07852352 Influenza saRNA 1 is a self-amplifying ribonucleic acid (RNA) vaccine. The completed clinical trial NCT05227001 was designed to evaluate this self-amplifying RNA vaccine for the prevention of influenza.